Recognition of LPS by the toll-like receptor 4 (TLR4)/MD-2 complex is a trigger of innate immune defense against bacterial invasion. However, excessive immune activation by this receptor complex causes septic shock and autoimmunity. Manipulation of TLR4 signaling represents a potential therapy that would avoid the detrimental consequences of unnecessary immune responses. In this study, we established two novel mAbs that inhibit LPS-induced human TLR4 activation. HT52 and HT4 mAbs inhibited LPS-induced nuclear factor-kB activation in TLR4/MD-2-expressing Ba/F3-transfected cells and cytokine production and up-regulation of CD86 in the human cell line U373 and PBMCs. These inhibitory activities were stronger than that of HTA125 mAb, which we previously reported. Immunofluorescent and biochemical studies using TLR4 deletion mutants revealed that HT52 and HT4 recognized spatially distinct regions on TLR4 irrespective of MD-2 association. The HT52 and HTA125 epitopes were localized within aa 50-190, while the HT4 epitope was formed only by the full length of TLR4. In addition, we demonstrated that HT52 and HT4 failed to compete with LPS for binding to TLR4/MD-2 but inhibited LPS-induced TLR4 internalization. Inhibitory activities were not due to the interaction with the Fcg receptor CD32. Our finding that binding of mAbs to at least two distinct regions on TLR4 inhibits LPS-dependent activation provides a novel method for manipulating TLR4 activation and also a rationale for designing drugs targeted to TLR4.
Introduction
Recognition of LPS, a cell wall component of Gram-negative bacteria, by the TLR4/MD-2 complex is an important trigger of innate immune defenses against bacterial invasion (1) . However, excessive immune activation by this receptor complex causes multiorgan failure due to septic shock (2, 3) . In addition, TLR4 signaling has been suggested to be involved in autoimmune disease. Mice that encode multiple copies of the TLR4 gene show lupus-like autoimmune symptoms (4) . In autoimmune-prone mice, TLR4 deficiency suppresses the progression of autoimmunity (5, 6) . Therefore, manipulation of TLR4 signaling represents an attractive therapy that would avoid the deleterious consequences of unnecessary or improper immune responses.
TLR4 is a type I transmembrane receptor that contains repeated LRR motifs in the extracellular region and a toll/IL-1R domain in the cytoplasmic region (7) . Secretory glycoprotein MD-2 is indispensable for TLR4 to recognize LPS and initiate signal transduction (8) . This molecule has a large hydrophobic pocket for ligand binding and contributes to the ligand specificity of the TLR4/MD-2 complex (9, 10) . Extensive studies on the interaction of TLR4, MD-2 and LPS revealed the residues critical for their interaction (11) (12) (13) (14) (15) (16) . Recent co-crystallographic analysis of TLR4/MD-2 (9) and TLR4/MD2/LPS (10) complexes has provided a better understanding of the molecular basis of LPS recognition. The extracellular domain of TLR4 is composed of N-terminal (aa 52-202), central (aa 203-348) and C-terminal (aa 349-582) domains, each of which consists of LRR 1-6, 7-12 and 13-22, respectively (7, 9, 10) . TLR4 forms a stable complex with MD-2 at the A and B patches on the concave surface of the N-terminal and central domains (9) . Five lipid chains of the lipid A moiety of LPS are completely buried inside the
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hydrophobic pocket of MD-2 (10) . An additional sixth lipid chain partially exposed outside this pocket interacts with the C-terminal domain of another TLR4 via hydrophobic phenylalanine residues (10, 13) . Two phosphate groups of the lipid A glucosamine disaccharide, which are localized outside the pocket, also interact with positively charged residues within the central and C-terminal domains of TLR4 and MD-2 (10, 14) . The resultant structural shift of the F126 loop in the MD-2-binding pocket causes the formation of a heterotetramer complex by two TLR4 and two MD-2 molecules. This is believed to initiate signal transduction by this complex (7, 10) . Pharmacological regulation of TLR4 activation has proved to be problematic. Competitive binding of a small compound in the LPS-binding pocket of MD-2 was proposed as a way of inhibiting LPS-dependent activation of TLR4. However, few synthetic LPS analogs with four lipid chains have been developed (17) (18) (19) . Eritoran is currently in a suspended clinical trial. The molecular basis of their antagonism is the inability to cause a structural shift of the F126 loop in the MD-2-binding pocket due to the improper positioning of phosphate groups in lipid A (7, 10) . Another possible means is blockade of the conformational change required for TLR4 signaling following LPS binding to MD-2, but the molecular basis for this allosteric regulation has not been determined.
The HTA125 mAb established by Akashi et al. (20) has long been used as to inhibit TLR4, while Dunn-Siegrist et al. (21) reported a novel inhibitory anti-TLR4 mAb, 15C1, which inhibited TLR4 by two mechanisms: binding to TLR4 and induction of an inhibitory signal by a Fc-Fcc receptor interaction. However, how the binding of both 15C1 and HTA125 to TLR4 inhibits activation remains unknown. In this study, we established a panel of mAbs against TLR4 and TLR4/ MD-2 and found that two TLR4-specific mAbs, HT52 and HT4, had potent inhibitory activities compared with HTA125. The epitopes of these mAbs were characterized by immunofluorescence and biochemical methods and compared with HTA125 and other nonfunctional mAbs. We found that HT52 has a specificity similar to that of HTA125, while HT4 recognizes a unique structure on TLR4. Furthermore, HT4 and HT52 do not compete with LPS for binding to TLR4/MD-2, whereas they inhibit LPS-induced TLR4 internalization. Inhibition was not mediated by interaction with the Fcc receptor CD32. Based on these findings, we suggest that binding mAbs to at least two different regions of TLR4 inhibits TLR4/MD-2 activation possibly through inhibiting TLR4 internalization without competing with LPS for receptor binding. This provides valuable information in the ongoing effort to establish a new molecular basis for the design of drugs targeted to TLR4. Inhibitory antihuman TLR4 mAbs 3
Methods

Cells
Ba/F3 and derived transfected cells were maintained in RPMI-1640 medium supplemented with 10% FCS, 100 U ml 
Reagents and antibodies
LPS from Escherichia coli ATCC 25922 was prepared as previously described (22) . Lipid A was obtained from the Peptide Institute (Osaka, Japan). Mouse antihuman TLR4 mAb (HTA125) (20) and mouse anti-mouse TLR4 mAb (UT15) (23) were produced in our laboratory. Other Abs were purchased from the following companies: mouse anti-FLAG-M2 mAb and agarose-immobilized FLAG-M2 mAb from Sigma-Aldrich Co. (St Louis, MO, USA); rabbit anti-GFP antibody from Invitrogen (Carlsbad, CA, USA); mouse anti-LPS mAb WN1 222-5 from Hycult Biotechnology (Uden, The Netherlands); alkaline phosphatase-conjugated goat anti-mouse IgG from American Qualex (San Clemente, CA, USA); alkaline phosphatase-conjugated goat anti-rabbit IgG from Kirkegaard and Perry Laboratories (Gaithersburg, MD, USA); phycoerythrin (PE)-conjugated goat anti-mouse IgG from Southern Biotechnology Associates (Birmingham, AL, USA); FITC-conjugated CD14 and PE-conjugated CD86 from Beckman Coulter (Brea, CA, USA) and PE-conjugated streptavidin from BD Biosciences (San Jose, CA, USA). Biotinylated (Bio-) antibodies were prepared using EZ-Link NHS-LC-Biotin (Pierce, Rockford, IL, USA) according to the manufacturer's instructions.
Establishment of stable HEK293 and Ba/F3-transfected cells expressing human TLR4 and MD-2 Stable HEK293-transfected clones expressing human TLR4 with or without C-terminally FLAG-tagged human MD-2 (MD-2F) were prepared as follows. A pEFBOS vector containing TLR4 and a pCAGGS1 vector containing MD-2F (16) were co-transfected into HEK293 cells using lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Following G418 selection, stable transfected clones expressing TLR4 or TLR4/MD-2F were screened by flow cytometry using the anti-TLR4 mAb HTA125 and anti-FLAG-M2 mAb.
Stable Ba/F3-transfected cells expressing human TLR4 with or without MD-2 were prepared as follows. To obtain a tagfree human MD-2 expression vector, the full coding region of MD-2 was amplified from a pCAGGS1 vector expressing MD-2F (16) by PCR using 5#-cgcctcgagttggagatattgaatcATGT-TACC-3# and 5#-ctcgcggccgcCTAATTTGAATTAGGTTGG-3# or stimulated with LPS (100 ng ml 
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primers and subcloned into pCAGGS1 at XhoI and NotI sites. This was co-transfected with a pCAGGS1 expression vector containing human TLR4 (16) into Ba/F3 cells by electroporation. Following G418 selection, stable clones expressing TLR4 or TLR4/MD-2 were screened by flow cytometry using HTA125 and HT59 (established in this study, see below) mAbs, respectively. Ba/F3-transfected cells co-expressing TLR4 and MD-2F were prepared as reported previously (16) and then co-transfected with human CD14 expression vector and pBabePuro by electroporation. After puromycin selection, CD14 co-expressing stable clones were screened by flow cytometry using CD14 mAb. Full coding sequence of CD14 was subcloned into a pBluescriptKS vector (Stratagene, La Jolla, CA, USA) from an EST clone (Accession No. BC010507, Open Biosystems, Livermore, CA, USA) using EcoRI and NotI sites CD14 expression vector was prepared by subcloning SalI/NotI-digested full coding sequence into pEFBOS vector (16) at XhoI and NotI Sites.
Establishment of mAbs against human TLR4/MD-2
TLR4
À/À mice (kindly provided by Dr S. Akira, Osaka University) on C57BL/6 genetic background were immunized intraperitoneally with 5 3 10 7 Ba/F3-transfected cells expressing human TLR4/MD-2F as an emulsion in complete Freund's adjuvant (Difco, Lawrence, KS, USA). Ten days later, mice were boosted with 1.5 3 10 7 of the same viable transfected cells. Three days later, spleen cells from immunized mice were fused with SP2/O myeloma cells using polyethylene glycol 1500 (Roche Applied Science, Indianapolis, IN, USA). Following HAT selection (Invitrogen), supernatants from hybridoma clones were screened by immunofluorescence staining against TLR4/MD-2F-expressing HEK293-transfected cells. Single clones were isolated by repeated limiting dilution cloning. Purified mAbs were obtained from ascitic fluids produced in SCID mice or in nude rats by caprylic acid precipitation followed by DEAE ion exchange chromatography. All animal experiments were done in accordance with the Saga Medical School guidelines for the care and treatment of animals used in experimentation.
Cell staining and flow cytometry
Cells were stained at 4°C with supernatant (1:2 dilution), 10 lg ml À1 of purified mAb or 1 lg ml À1 of purified Bio-mAb in staining buffer (HBSS containing 2% FCS and 0.1% azide for Ba/F3-derived cells and whole blood cells; PBS containing 3% FCS, 10 mM EDTA and 0.1% azide for HEK293-derived cells). After washing three times, cells were incubated with PE-conjugated secondary antibodies or streptavidin and subjected to flow cytometry analysis using a FACScan or FACScalibur (Becton Dickinson, Franklin Lakes, NJ, USA). In case of CD14/CD86 staining of whole blood cells, cells were stained after hemolysis. 
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For cross-blocking immunofluorescence analysis of anti-TLR4 or TLR4/MD-2 mAb, TLR4/MD-2-expressing Ba/F3-transfected cells were incubated at 4°C with 10 lg ml À1 of unlabeled mAb. After 5 min, 1 lg ml À1 Bio-mAb was added and again incubated at 4°C for 15 min. After washing three times with staining buffer, cells were incubated with PEconjugated streptavidin for 15 min at 4°C and analyzed by flow cytometry.
For TLR4 internalization analysis, LPS-stimulated cells were washed twice by staining buffer and then stained with Bio-mAbs.
Nuclear factor-jB reporter assay in Ba/F3-transfected cells
Ten thousand Ba/F3 cells expressing TLR4/MD-2F and carrying the p55IgjBLuc nuclear factor-jB (NF-jB) reporter gene (provided by Dr K. Miyake, Tokyo University) were stimulated with LPS in a 96-well round-bottom plate in 100 ll culture medium for 5 h in the presence of anti-TLR4 mAb. Luciferase activity was measured using Steady-Glo luciferase reagent (Promega, Madison, WI, USA) and expressed as the fold-increase compared with nonstimulated cells.
Cytokine production by U373 cell lines, human PBMCs and whole blood cells U373 cells (5 3 10 4 ) were cultured for 24 h in 500 ll culture medium in 48-well plates and then stimulated with LPS for 6 h in the presence of the indicated amounts of anti-TLR4 mAb. PBMCs (1 3 10 5 ) from healthy donors were stimulated in 100 ll culture medium in a 96-well plate with lipid A for 6 h (IL-6 and TNF-a) or 24 h (IL-12p40) in the presence of the indicated amounts of anti-TLR4 mAb. One hundred microlitter of heparinized whole blood diluted with equal volume of RPMI were stimulated in a 96-well plate as well. Cytokine levels in culture supernatants and plasma were measured using ELISA kits (IL-6, eBiosciences, San Diego, CA, USA; TNF-a and IL-12p40, BioLegend, San Diego, CA). Experiments using human PBMCs were performed under the guidelines of the Ethical Committee for Research at Saga University, Faculty of Medicine.
Establishment of stable HEK293-transfected cells expressing C-terminally enhanced GFP-tagged human TLR4 (TLR4G) deletion mutants
An enhanced GFP (EGFP)-tagged full-length human TLR4 expression vector was constructed using a human TLR4/pEF-BOS vector (16) , which has an XhoI site upstream of, and a BamHI site downstream of, the TLR4 gene as cloning sites. The NotI site is located just downstream of BamHI. The Cterminal portion of TLR4 without a stop codon was amplified from a pCAGGS1 vector containing the full coding sequence of TLR4 (16) by PCR using 5#-CCAGATATCTTCACAGAGCT-GAG-3# and 5#-tccggatccGATAGATGTTGCTTCCTGCC-3# primers. This PCR fragment was subcloned into the human TLR4/pEFBOS vector (16) using an EcoRV site on the TLR4 side and a BamHI site on the vector side (both are underlined within primer sequences). Subsequently, the full coding sequence of EGFP was amplified from the pEGFP-N1 vector (Clontech, Mountain View, CA, USA) by PCR using 5#-gtcggatccATGGTGAGCAAGGGCGA-3# and 5#-gtcgcggccgct TTACTTGTACAGCTCGTC-3# primers and subcloned in frame into a BamHI site and a NotI site in the vector to express the TLR4G molecule (TLR4G/pEFBOS).
The expression vectors for creating the TLR4G deletion mutants were constructed as follows. cDNA fragments coding for aa 1-49 and 1-190 of TLR4 were amplified from a TLR4/ pEFBOS vector (16) by PCR using a common sense primer, 5#-ttctcaagcctcagacagtgg-3# (which anneals vector sequences upstream of TLR4 gene) and the anti-sense primers: 5#-gaggttaacGGGGATTTTGTAGAAATTCAG-3# for aa 1-49 or 5#-ctgtgttaacAATACTTTGAATCTTGTTGC-3# for aa 1-190, respectively. These PCR products were subcloned into TLR4G/pEFBOS (described above) at XhoI (which is located downstream of the common sense primer) and HpaI sites in the TLR4 gene (underlined within primer sequences). The resultant vectors, TLR4D50-337G/pEFBOS and TLR4D191- 
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337G/pEFBOS, express TLR4G lacking aa 50-337 (TLR4D50-337G) and aa 191-337 (TLR4D191-337G), respectively. A cDNA fragment coding for aa 580-839 of TLR4 was amplified by PCR using the sense 5#-actgttaacGACTTTGCTTG-TACTTGTG-3# and anti-sense 5#-tccggatccGATAGATGTTGCT-TCCTGCC-3# primers and then subcloned into TLR4G/ pEFBOS (described above) at an HpaI site within the TLR4 gene and a BamHI site located between TLR4 and EGFP. The resultant construct, TLR4D340-579G/pEFBOS, expresses TLR4G lacking aa 340-579 (TLR4D340-579G).
TLR4G deletion pEFBOS constructs were transfected into HEK293 cells with a pBabePuro selection vector via lipofectamine 2000. After puromycin selection, stable transfected clones were screened by EGFP fluorescence and flow cytometry.
Immunoprecipitation-western blotting
Stable HEK293-transfected cells, which were 80% confluent on a 10-cm-diameter dish, were washed twice with PBS containing 1 mM EDTA and lysed in 1 ml of 20 mM Tris buffer (pH 7.5) containing 150 mM NaCl, 1 mM EDTA, 1% Triton-X100 and 1 mM PMSF at 4°C for 20 min. After centrifugation at 15 000 3 g for 15 min at 4°C, cell lysates were incubated with 25 ll of HT4-, HT52-or HTA125-immobilized protein G Sepharose (Amersham Biosciences, Piscataway, NJ, USA) for 2 h at 4°C with gentle rotation. As a positive control, rabbit anti-GFP polyclonal antibody directly immobilized to Affi-Gel 10 (Bio-Rad, Hercules, CA, USA) was used (24) . Beads were washed three times with lysis buffer and bound proteins were eluted by boiling in Laemmli buffer. Eluted proteins were resolved on a 7.5% SDS-PAGE gel and transferred to Immobilon-P membrane filters (Millipore Co., Bedford, MA, USA). Immunoreactivity with anti-GFP polyclonal antibody was visualized by adding alkaline phosphatase-conjugated anti-rabbit IgG and BCIP/NBT Color Development Substrate (Promega).
LPS-binding assay
LPS bound to TLR4/MD-2 was detected as reported previously (16) . Briefly, 2-10 3 10 7 Ba/F3-transfected cells expressing the TLR4/MD-2F/CD14/NF-jB reporter gene (provided by Dr K. Miyake) were pre-incubated with 10 lg ml À1 HT4 or HT52 mAb for 5 min, then stimulated with LPS for 30 min. After washing with serum-free medium, cells were lysed in lysis buffer for 30 min at 4°C. After centrifugation at 15 000 3 g for 5 min, the supernatants were incubated with FLAG-M2 mAb-immobilized agarose gels at 4°C for 2 h. Gels were washed three times with lysis buffer and boiled in Laemmli buffer. The precipitated materials were resolved by SDS-PAGE and probed with the anti-LPS mAb WN1 222-5 or FLAG-M2.
Results
Establishment of antihuman TLR4/MD-2 mAbs
By immunizing TLR4
À/À mice with Ba/F3 cells expressing human TLR4/MD-2F, we obtained nearly 3000 positive wells from four independent fusion experiments. Of these, around Inhibitory antihuman TLR4 mAbs 7 70 showed positive staining against HEK293 cells expressing TLR4/MD-2F. After limiting dilution cloning, 22 independent hybridoma clones were obtained and 13 of these mAbs were successfully purified from ascitic fluids. The typical staining pattern of purified mAbs from these hybridomas against stable TLR4 and TLR4/MD-2-transfected cells are shown in Fig. 1 . Most mAbs, like the established HTA125 mAb clone (20) , showed reactivity against TLR4 irrespective of the presence of MD-2. Addition of an FLAG tag into MD-2 molecules did not interfere with epitope recognition, which suggests that the epitopes for these mAbs reside on the TLR4 chain and not on the MD-2 chain. However, three mAbs (HT17, HT26 and HT59) reacted against TLR4/MD-2-, but not against TLR4-expressing cells, suggesting that the epitopes of these mAbs comprised a combinatorial structure produced by the association of TLR4 with MD-2. In addition, no mAbs reacted with mouse TLR4/MD-2-expressing Ba/F3 cells (data not shown). The characteristics of purified mAbs established in this study are summarized in Table 1 .
Inhibitory antihuman TLR4 mAbs
We then examined the functional activities of antihuman TLR4/MD-2 mAbs. Supernatants from 22 independent hybridoma clones were screened for agonistic and antagonistic activities using reporter Ba/F3-transfected cells carrying human TLR4/MD-2 and NF-jB reporter genes. None of the supernatants or purified mAbs showed agonistic activities, at up to a 1:2 dilution and 10 lg ml À1 , respectively (data not shown). In contrast, the supernatants from 2 of 22 hybridomas showed inhibitory activities when added to reporter transfected cells stimulated by LPS (data not shown). When we tested mAbs purified from these hybridomas, both HT4 and HT52 mAbs showed dose-dependent inhibition of reporter transfected cells stimulated by varying amounts of LPS (Fig. 2A) . Inhibition by both of these mAbs was stronger than that of HTA125 (20) . Consistent with these results, HT4 and HT52 mAbs inhibited LPS-induced IL-6 production by the human glioblastoma cell line U373 (Fig. 2B) . In human PBMCs and whole blood cells, IL-6, TNF-a and IL12p40 production after stimulation with synthetic lipid A was also blocked by the HT4 and HT52 mAbs (Fig. 2C and D) . In addition to cytokine production, we further asked for inhibitory activities of these mAbs in up-regulation of costimulatory molecule (Fig. 3) . Lipid A-induced up-regulation of CD86 in CD14 + monocytes was inhibited by the incubation with HT4 and HT52. In most cases, the HT52 and HT4 mAbs showed greater inhibition than the HTA125 mAb. Considering clinical application, we further tested the effect of post-incubation with HT4 and HT52 on cytokine production. We found that these mAbs show inhibitory activities even if these were added 30 min after lipid A stimulation although the inhibition is slightly attenuated compared with preaddition of mAbs (Fig. 4) . 
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Epitope analysis of inhibitory mAbs
We examined the epitopes recognized by inhibitory mAbs. We used immunofluorescent cross-blocking analysis with Ba/F3 cells expressing TLR4/MD-2. After pre-incubation with unlabeled mAb, cells were stained with Bio-mAb followed by PE-streptavidin. As shown in Fig. 5A , Bio-HT4 staining was not cross-blocked by unlabeled HT52 and HTA125. Unlabeled HT4 failed to inhibit the reaction of Bio-HT52 and Bio-HTA125 with TLR4, which suggests that the structure recognized by HT4 is spatially distinct from those recognized by HT52 or HTA125. Moreover, no other mAbs, with the exception of blocking by HT4, cross-blocked Bio-HT4 binding. This suggests that HT4 recognizes a unique structure of TLR4. In contrast, Bio-HT52 staining was cross-blocked by unlabeled HTA125, and unlabeled HT52 cross-blocked Bio-HTA125 staining. In addition to HT52 and HTA125, we found that HT16 and HT58 also showed crossblocking of HT52 and HTA125, but not HT4, despite having no inhibitory activity against TLR4. Notably, cross-blocking analysis with Bio-HT17, HT26 and HT59, which recognize the TLR4/MD-2 complex, revealed that the HT52 and HTA125 epitopes were clearly distinguishable from those of HT16 and HT58. As shown in Fig. 5B, HT16 and HT58 cross-blocked Bio-HT59, but not Bio-HT17 and HT26 binding, although these mAbs recognize the TLR4 chain. In contrast, HT52 and HTA125 did not cross-block the three complex-type mAbs. These results indicate that the epitopes of the inhibitory mAbs HT52 and HTA125 are closely related. This subtle difference from HT16 and HT58 in terms of competition with HT59 might assist in determining the inhibitory activities of HT52 and HTA125.
Next, we located the epitopes using HEK293 cells expressing TLR4 deletion mutants tagged with EGFP at the C-terminus (Fig. 6A) . TLR4D50-337G lacks both the Nterminal and central domains in the extracellular TLR4G. TLR4GD191-337 and TLR4D340-579G lack only the central and C-terminal domains, respectively. As shown in Fig. 6B , HT52 reacted to cells with all TLR4 deletion mutants, except for TLR4D50-337G. Since HT52 recognized TLR4D191-337G, its epitope must lie between aa 50 and 190 of TLR4. In addition, HTA125 showed a similar staining pattern to HT52, suggesting that its epitope is proximal to that of HT52. In contrast, HT4 reacted only to cells expressing a complete TLR4 molecule. HT4 staining was negative for cells expressing any other deletion mutant. This indicates that the HT4 epitope differs from those of HT52 and HTA125. This is consistent with the findings of the crossblocking experiments. The HT4 epitope may thus be composed of discontinuous sequences and is expressed only on the complete TLR4 molecule.
The lack of positive TLR4D50-337G staining by our mAbs, including HT52 and HTA125 (Fig. 6B , data not shown), was not due to poor expression of the constructs since these cells were EGFP-positive (data not shown). However, the negative staining may have been due to a lack of cell surface translocation. To verify the immunofluorescence results, we performed immunoprecipitation (IP)-western blotting (WB) experiments using the deletion mutants (Fig. 6C) . After the lysis, TLR4G deletion mutants were immunoprecipitated with HT52-or HTA125-coupled beads and then subjected to WB with anti-GFP antibody. HT52 and HTA125 precipitated full-length TLR4G, TLR4D191-337G and TLR4D340-579G. However, both mAbs did not precipitate TLR4D50-337G mutants. A signal was detected from TLR4D50-337G when IP was performed with anti-GFP antibody. These results suggest that the HT52 and HTA125 epitope is located within aa 50-190 of TLR4. Consistent with immunofluorescence results, HT4 failed to precipitate any deletion mutants except for full-length TLR4G.
HT4 and HT52 inhibition is not mediated by competition for LPS binding to TLR4/MD-2 or by induction of an inhibitory signal via Fc-Fcc receptor interaction One possible mechanism of mAb inhibition of LPS-induced TLR4 activation is competition for LPS binding to MD-2. Therefore, we examined whether HT4 and HT52 compete with LPS (Fig. 7) . Ba/F3 cells expressing TLR4/MD-2F were pre-incubated with either HT52 or HT4 mAb, followed by incubation with LPS. Co-precipitation of LPS with TLR4/MD-2F was examined by IP with FLAG mAb followed by WB with anti-LPS mAb. No reduction in LPS co-precipitation resulted from pre-incubation with HT4 or HT52, suggesting that competition for LPS binding to TLR4/MD-2 is not a mechanism of HT4 and HT52 inhibition.
Dunn-Siegrist et al. Inhibitory antihuman TLR4 mAbs 505 interaction on target cells. Inhibitory activity was blocked by pre-incubation with CD32 blocking mAb AT10. Therefore, we investigated the impact of AT10 on the inhibitory activities of our mAbs to reveal the contribution of CD32. As shown in Fig. 8 , pre-incubation of PBMCs with AT10 did not ameliorate the inhibition of either lipid A-induced IL-6, TNF-a or IL-12p40 production by HT52 and HT4, which indicates that Fcc receptor-mediated suppressive signaling is not the primary mechanism of HT4 and HT52 inhibition. This is also supported by our observation that U373 cells, whose IL-6 production was inhibited by the mAbs, do not express CD32, as determined by flow cytometry (data not shown).
HT4 and HT52 block TLR4 internalization induced by LPS
Another possible mechanism is inhibition of LPS-induced TLR4 internalization. To test this possibility, Ba/F3 cells expressing TLR4/MD-2F were pre-incubated with either HT52 or HT4 mAb prior to 2 h of LPS stimulation and then stained with Bio-HT53 or Bio-HT59, which recognize TLR4 chain and TLR4/MD-2 complex. Expectedly, surface TLR4 level was decreased by LPS stimulation, and its decrease was clearly prevented by HT4 and HT52 (Fig. 9) . Incubation with mAbs alone did not interfere the staining with Bio-HT53 and Bio-HT59, which indicates that inhibition of TLR4 internalization is not due to epitope overlapping with HT4 and HT52. These results suggest that inhibition of TLR4 internalization is at lease in part a mechanism of inhibitory activities of HT4 and HT52.
Discussion
In this study, we developed antihuman TLR4 mAbs (HT4 and HT52) that potently inhibit the LPS-induced NF-jB activation of Ba/F3-transfected cells expressing TLR4/MD-2. They inhibited inflammatory cytokine production in U373 cells stimulated by LPS and in PBMCs and whole blood cells stimulated by lipid A. CD86 up-regulation was also blocked in CD14 + monocytes. The specificity of these mAbs, as revealed by cells transfected with TLR4 and TLR4/MD-2, indicated that both epitopes are mapped on the TLR4 chain, irrespective of the presence of MD-2. Precise epitope characterization of these mAbs and HTA125 by immunofluorescence and biochemical techniques using TLR4 deletion mutants showed that the epitopes of HT52 and HTA125 are located in a different region than that recognized by HT4. Epitopes recognized by HT52 mAb and HTA125 mAb reside between aa 50 and 190 of TLR4 molecule because these mAbs did not recognize a TLR4D50-337G deletion mutant but recognized both TLR4D191-337G and TLR4D340-579G mutants in both flow cytometric and biochemical analysis. The HT4 mAb epitope could be formed by discontinuous sequences of the TLR4 molecule because none of the deletion mutants reacted to HT4 in FACS analysis. Biochemical analysis of HT4 epitope showed a relatively weak signal corresponding to the expected size of TLR4D50-337G deletion mutant. This could result from the fact that partial sequences of HT4 epitope locate outside of this deleted portion and HT4 mAb weakly recognized such incomplete sequences.
Dunn-Siegrist et al. (21) reported a unique mAb, 15C1, which neutralizes LPS-stimulated activation of human PBMCs and cell lines in an Fcc receptor-associated manner. They demonstrated that the 15C1 epitope resides in the second portion (aa 289-375) of the C-terminal domain of TLR4. This is clearly different from those of HT52 and HT4. HT52 was reactive to TLR4D191-337G and TLR4D340-579G. The HT4 epitope is present only on naive TLR4. Like HT52 and HT4, 15C1 demonstrated stronger inhibitory activity compared with HTA125. However, the mechanism underlying inhibition by 15C1 differs from that of our inhibitory mAbs because the activity of 15C1 is partially mediated by the Fcc receptor.
Inhibition by HT52 and HT4 could not be due to blocking of LPS binding because a pull-down assay revealed that these mAbs did not compete with LPS for binding to TLR4/ MD-2. Rather, the binding of inhibitory mAbs to TLR4 might confer a conformation that is refractory to the LPS-induced conformation change required for signaling. Amino acids 50-190 map to the concave surface of the N-terminal domain of extracellular TLR4. This region contains the A patch for the constitutive association of TLR4 with MD-2 (9) but is not directly involved in hydrophilic or hydrophobic interactions with LPS/MD-2 (10). According to co-crystallography, repositioning of the F126 loop in the MD-2-binding pocket enables the formation of a dimerization interface (10) . The Cterminal domain of TLR4 is bent by 10°between the central and C-terminal domains (10) . Therefore, the hindrance that resulted from the binding of HT52 and HT4 might have rendered TLR4/MD-2 refractory to either the induction of an active conformational change, such as TLR4 bending or the formation of a dimerization interface. Actually, several small compounds with the ability to inhibit TLR4 dimerization have been reported to inhibit murine TLR4 activation (25, 26) . As another possible mechanism, we demonstrated the inhibition of LPS-induced TLR4 internalization by HT4 and HT52 mAbs. It has been reported that TLR4 signal originates both from cell surface and from endosome after internalization (27, 28) . These suggest that inhibition of internalization is a part of mechanism of HT4 and HT52 inhibition. Of course, further investigation is required to uncover overall molecular mechanism, in particular, in terms of TLR4 dimerization.
The presence of multiple sites for inhibition by mAb has an important implication for manipulating TLR4 signaling. Combinatorial use of several reagents that recognize spatially different regions of TLR4 may result in more potent inhibition of LPS stimulation due to collaborative effects. Indeed, concomitant use of HT52 and HT4 was more strongly inhibitory of LPS-induced TLR4 activation than by either mAb alone (data not shown). In addition, combination with LPS analogs that compete with LPS for binding may inhibit TLR4 activation at multiple steps, i.e. LPS binding, the resulting conformational change and internalization. To our surprise, addition of HT4 or HT52 30 min after LPS stimulation was still inhibitory for cytokine production by PBMCs. Although the mechanisms for this are totally unclear, it could be possible that these inhibitory mAbs might transmit inhibitory signals by inducing nonidentified conformational changes of TLR4 after binding to their epitopes. Anyway, inhibitory effects Inhibitory antihuman TLR4 mAbs 11 exerted by these mAbs after cells are activated could have a potential clinical benefit for treatment of patients with sepsis and several autoimmune inflammatory diseases.
In conclusion, we revealed the presence of at least two potential sites on TLR4 that regulate LPS-induced activation. Further analysis of the TLR4 structures that are recognized by these inhibitory mAbs would provide fundamental information for developing a novel strategy to manipulate TLR4 activation and a molecular basis for designing TLR4-targeted drugs. We also hope that HT52 and HT4 are useful for developing clinically applicable inhibitory TLR4 mAbs.
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